<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049161</url>
  </required_header>
  <id_info>
    <org_study_id>GNC-402</org_study_id>
    <secondary_id>2021-001973-21</secondary_id>
    <nct_id>NCT05049161</nct_id>
  </id_info>
  <brief_title>A Long-term Extension of Study GNC-401</brief_title>
  <official_title>A Long-term Extension of Study GNC-401 With Temelimab in Patients With Relapsing Forms of Multiple Sclerosis (RMS) Under Treatment With Rituximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeNeuro Innovation SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GeNeuro SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II study is a monocenter, long-term extension study of study GNC-401 and will&#xD;
      start after individual completion of Week 48 of the GNC-401 study. At entry, all patients&#xD;
      will receive active treatment with temelimab. The patients of the placebo group in study&#xD;
      GNC-401 will be re-randomized to temelimab 18 mg/kg, 36 mg/kg or 54 mg/kg (1:1:1), while the&#xD;
      patients who received temelimab in study GNC-401 will continue with the same dose in study&#xD;
      GNC-402. Following final analysis of the results of the GNC-401 study, the Sponsor may switch&#xD;
      all patients to an optimal dose of temelimab based on safety and efficacy demonstrated in the&#xD;
      GNC-401 study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability:adverse event</measure>
    <time_frame>48 weeks</time_frame>
    <description>Number of Patients With Treatment-Related Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in Brain parenchymal volume fraction at Week 48 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>48 weeks</time_frame>
    <description>change in magnetization transfer Saturation (MTSat) in periventricular NAWM at at Week 48 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in thalamic volume fraction at Week 48 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in magnetization Transfer Saturation (MTSat) in cortex at Week 48 compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in T1 and T2 lesion volume at Week 48 compared to Baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Temelimab 18 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly IV repeated dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Temelimab 36 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly IV repeated dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Temelimab 54 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monthly IV repeated dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temelimab 18 mg/kg</intervention_name>
    <description>temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)</description>
    <arm_group_label>Temelimab 18 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temelimab 36mg/kg</intervention_name>
    <description>temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)</description>
    <arm_group_label>Temelimab 36 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temelimab 54 mg/kg</intervention_name>
    <description>temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)</description>
    <arm_group_label>Temelimab 54 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. The patient has given written informed consent to participate in the study;&#xD;
&#xD;
          2. Current diagnosis of RMS, based on the McDonald 2017 criteria ;&#xD;
&#xD;
          3. Patients must have completed study GNC-401. Completion is defined as having performed&#xD;
             the Week 48 assessments of study GNC 401;&#xD;
&#xD;
          4. Have no clinical (relapses) or MRI signs (≥2 new T2 lesions of &gt;10 mm diameter) of&#xD;
             acute MS disease activity, based on the Week 48 MRI of study GNC 401, or, if yes, been&#xD;
             retreated prior to study entry with rituximab;&#xD;
&#xD;
          5. Have a B cell count ≤0.05 x 109 CD19 cells/L (assessed at the end of study GNC 401, or&#xD;
             before inclusion in this study GNC 402 (available result from routine clinical&#xD;
             practice); if not retreated with rituximab before entering study GNC-402, monthly&#xD;
             B-cell count will be executed and retreatment will be considered by the treating&#xD;
             physician when B-cells are &gt;0.05 x 109 CD19 cells/L);&#xD;
&#xD;
        Main exclusion criteria&#xD;
&#xD;
          1. The emergence of any disease diagnosis during the course of study GNC-401 that is not&#xD;
             due to MS and could better explain the patient's neurological signs and symptoms;&#xD;
&#xD;
          2. Body weight ≤40 kg;&#xD;
&#xD;
          3. Contraindication to continue rituximab therapy;&#xD;
&#xD;
          4. Has received rituximab less than 12 days prior to study entry;&#xD;
&#xD;
          5. Use of any of the following medications since Week 48 of the GNC 401 study:&#xD;
&#xD;
               1. Interferon (IFN) β, glatiramer acetate, IV immunoglobulin (IVIG), dimethyl&#xD;
                  fumarate or teriflunomide;&#xD;
&#xD;
               2. Natalizumab, mitoxantrone, cladribine, alemtuzumab, cyclophosphamide, systemic&#xD;
                  cytotoxic therapy, total lymphoid irradiation, and/or bone marrow&#xD;
                  transplantation;&#xD;
&#xD;
               3. Highly potent immune modulating therapy, such as: ocrelizumab, ofatumumab,&#xD;
                  fingolimod, siponimod, ozanimod or anti-cytokine therapy, plasmapheresis or&#xD;
                  azathioprine;&#xD;
&#xD;
               4. Any experimental drugs for the treatment of MS;&#xD;
&#xD;
          6. Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or greater lymphopenia&#xD;
             (based on Week 48 of study GNC 401);&#xD;
&#xD;
          7. Any major medical or psychiatric disorder that would affect the capacity of the&#xD;
             patient to fulfill the requirements of the study, including:&#xD;
&#xD;
               1. Diagnosis or history of schizophrenia;&#xD;
&#xD;
               2. Current diagnosis of moderate to severe bipolar disorder, major depressive&#xD;
                  disorder, major depressive episode, history of suicide attempt, or current&#xD;
                  suicidal ideation;&#xD;
&#xD;
               3. Current or past (within the last 2 years) alcohol or drug abuse;&#xD;
&#xD;
          8. History or presence of serious or acute heart disease such as uncontrolled cardiac&#xD;
             dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or&#xD;
             uncontrolled congestive heart failure (New York Heart Association [NYHA] class 3 or&#xD;
             4);&#xD;
&#xD;
          9. Known inability to undergo an MRI scan;&#xD;
&#xD;
         10. Contraindications to the use of 5% glucose solution for infusion;&#xD;
&#xD;
         11. Inability to follow study instructions, or complete study assessments, as defined by&#xD;
             the protocol;&#xD;
&#xD;
         12. Any history of cancer with the exceptions of basal cell carcinoma and/or carcinoma in&#xD;
             situ of the cervix, and only if successfully treated by complete surgical resection,&#xD;
             with documented clean margins and any medically unstable condition as determined by&#xD;
             the Investigator;&#xD;
&#xD;
         13. Pregnant or breastfeeding women;&#xD;
&#xD;
         14. Abnormal liver function tests: aspartate aminotransferase (AST) or alanine&#xD;
             aminotransferase (ALT) &gt;2 times upper limit of normal range (ULN), or conjugated&#xD;
             bilirubin &gt;2 times ULN, or alkaline phosphatase (AP) or gamma-glutamyl transferase&#xD;
             (GGT) &gt;3 times ULN;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Leppert, MD</last_name>
    <role>Study Director</role>
    <affiliation>GeNeuro Innovation SAS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Leppert, MD</last_name>
    <phone>0041225524800</phone>
    <email>dl@geneuro.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie Berthuy</last_name>
    <phone>0041225524800</phone>
    <email>nab@geneuro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Neurology, Academic Specialist Center</name>
      <address>
        <city>Stockholm</city>
        <zip>113 65</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Piehl</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing Forms of Multiple Sclerosis</keyword>
  <keyword>GNbAC1</keyword>
  <keyword>Human Endogenous Retrovirus Type W</keyword>
  <keyword>HERV-W</keyword>
  <keyword>Temelimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

